AMGN.TO Amgen CDR (CAD Hedged)

Healthcare Drug Manufacturers - General Toronto Exchange
- CAD
Market cap
-
P/E
27.0x
P/B
16.67x
ROE
74.9%
Dividend yield
0.66%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AMGN.TO undervalued?

Graham number

The Graham number of Amgen CDR (CAD Hedged) cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amgen CDR (CAD Hedged) fundamental analysis

No fundamental analysis for Amgen CDR (CAD Hedged) yet.

Amgen CDR (CAD Hedged) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amgen CDR (CAD Hedged)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which re…

Full company profile